Precision Gene Silencing with siRNA Therapeutics
RNA interference (RNAi) represents a powerful post-transcriptional gene regulation mechanism with significant therapeutic potential across cancer, viral infections, neurodegenerative diseases, and inflammatory disorders. Therapeutic RNAi development involves the design, optimization, and validation of small interfering RNA (siRNA) molecules that selectively downregulate target gene expression via degradation of complementary mRNA. This service is designed for preclinical evaluation of gene silencing efficacy, delivery specificity, and dose-responsive knockdown using qPCR-based quantitation.
Target Identification and siRNA Design
Development begins with rigorous in silico design of siRNA duplexes targeting specific mRNA transcripts. This process includes screening for off-target effects, secondary structure predictions, and thermodynamic optimization of the antisense strand. Custom siRNA candidates are synthesized and pre-screened using cell-based reporter assays or in vitro cleavage systems to ensure potency and specificity before advancing into cellular or animal models.
Transfection and Delivery Optimization
Efficient delivery of siRNA into target cells or tissues is achieved using lipid-based transfection reagents, electroporation buffers, or nanoparticle encapsulation platforms. Transfection parameters are optimized for cell viability, intracellular localization, and reproducible delivery efficiency. Delivery validation is performed using fluorescently labeled siRNA, flow cytometry, or confocal imaging to assess cytosolic distribution and uptake kinetics.
Quantitative mRNA Knockdown Analysis via qPCR
Quantitation of gene silencing is performed using real-time quantitative reverse transcription PCR (qRT-PCR). This method provides high sensitivity and dynamic range for detecting reductions in mRNA transcript levels. Total RNA is isolated post-transfection, converted into cDNA, and amplified using target-specific primers. Knockdown efficiency is calculated relative to untreated controls or scrambled siRNA-transfected cells, with normalization to housekeeping genes for internal consistency. Cycle threshold (Ct) values are statistically analyzed to determine percent knockdown and reproducibility across biological replicates.
Validation of On-Target Effects
To distinguish true on-target silencing from non-specific effects, multiple siRNA sequences targeting different regions of the same gene are evaluated in parallel. mRNA knockdown is correlated with downstream protein expression changes using Western blotting, immunocytochemistry, or ELISA-based detection. Functional assays—such as cell viability, apoptosis, or migration—are used to confirm phenotypic consequences of gene knockdown in relevant biological systems.
Applications in Preclinical RNA Therapeutic Development
This service supports the development of RNAi-based therapeutics by generating proof-of-concept data for target inhibition. It is applicable to oncology drug development, antiviral compound screening, inflammatory pathway modulation, and metabolic gene function studies. qPCR validation of knockdown efficiency provides regulatory-grade data suitable for preclinical toxicology programs, target validation studies, and IND submissions.
Altogen Labs Support for Therapeutic RNAi Studies
Altogen Labs offers complete RNAi development solutions, including custom siRNA design, delivery formulation, in vitro transfection, and qPCR assay development. Their laboratories support both exploratory and GLP-compliant RNAi studies, integrating knockdown validation with functional assays and toxicology endpoints. For in vivo applications, services include tissue-specific RNAi delivery, gene silencing analysis, and biodistribution profiling, enabling comprehensive therapeutic development of RNA-based interventions.